Publications
387
Citations
15,621
Est. group size
—
Recurring co-author estimate
Active years
61
Publishing since 1965
This researcher works primarily in oncology, with a strong focus on prostate cancer treatment—particularly clinical trials evaluating radiation therapy approaches (such as hypofractionated versus conventional radiotherapy) and drug therapies for advanced disease. The publication record also spans other cancers, health systems research, and policy-oriented work on cost-benefit analysis and regulation, suggesting the name may span more than one individual's output.
Publication activity has slowed from about ten papers per year in 2017-2018 to an average of roughly 2-3 per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Health System Level Barriers to Integrated Care for Comorbid Chronic Obstructive Pulmonary Disease and Cardiovascular Disease in Populations Experiencing Health Care Inequity
American Journal of Respiratory and Critical Care Medicine · 2025
- Understanding how on‐farm biosecurity perceptions and practices of New South Wales sheep producers have been impacted by the 2022 foot‐and‐mouth disease outbreak in Indonesia
Australian Veterinary Journal · 2025
- Index
Edward Elgar Publishing eBooks · 2024
- Co‐Benefits, Countervailing Risks, and Cost–Benefit Analysis
2024
- The rise of the administrative state
Edward Elgar Publishing eBooks · 2024
- SYNTHETIC VERSUS AUTOLOGOUS RECONSTRUCTION (SYN-VAR) RANDOMIZED CONTROLLED TRIAL OF THE MEDIAL PATELLOFEMORAL LIGAMENT
Orthopaedic Proceedings · 2023
- Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
The Lancet Oncology · 2023
- Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial
International Journal of Radiation Oncology*Biology*Physics · 2022
- Is California’s Electric Vehicle Rebate Regressive? A Distributional Analysis
Journal of Benefit-Cost Analysis · 2022
- 549P Results of a first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours (NuTide:301)
Annals of Oncology · 2021
- 431P The FOCUS4-N trial results and individual patient data meta-analysis (IPDM) of maintenance therapy versus active monitoring for patients with metastatic colorectal cancer (mCRC)
Annals of Oncology · 2021
- POS1089 ASSOCIATION BETWEEN PAIN SEVERITY AND HEALTHCARE UTILIZATION IN AN OSTEOARTHRITIS POPULATION: AN 18-YEAR RETROSPECTIVE COHORT STUDY
Annals of the Rheumatic Diseases · 2021
- The Benefits and Costs of Automotive Regulations for Low-Income Americans
Journal of Benefit-Cost Analysis · 2021
- Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)
European Urology Oncology · 2021
- 726P Collecting duct and renal medullary carcinoma: A population based analysis
Annals of Oncology · 2020
- Journal of Benefit-Cost Analysis×4
- Journal of Risk Research×3
- International Journal of Radiation Oncology*Biology*Physics×3
- Journal of Clinical Oncology×3
- Annals of Oncology×3
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile